Literature DB >> 19706537

In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation.

Hiroyuki Kishimoto1, Ming Zhao, Katsuhiro Hayashi, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara, Sheldon Penman, Robert M Hoffman.   

Abstract

Cancer surgery requires the complete and precise identification of malignant tissue margins including the smallest disseminated lesions. Internal green fluorescent protein (GFP) fluorescence can intensely illuminate even single cells but requires GFP sequence transcription within the cell. Introducing and selectively activating the GFP gene in malignant tissue in vivo is made possible by the development of OBP-401, a telomerase-dependent, replication-competent adenovirus expressing GFP. This potentially powerful adjunct to surgical navigation was demonstrated in 2 nude mouse models that represent difficult surgical challenges--the resection of widely disseminated cancer. HCT-116, a model of intraperitoneal disseminated human colon cancer, was labeled by virus injection into the peritoneal cavity. A549, a model of pleural dissemination of human lung cancer, was labeled by virus administered into the pleural cavity. Only the malignant tissue fluoresced brightly in both models. In the intraperitoneal model of disseminated cancer, fluorescence-guided surgery enabled resection of all tumor nodules labeled with GFP by OBP-401. The data in this report suggest that adenoviral-GFP labeling tumors in patients can enable fluorescence-guided surgical navigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706537      PMCID: PMC2732810          DOI: 10.1073/pnas.0906388106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  Facile whole-body imaging of internal fluorescent tumors in mice with an LED flashlight.

Authors:  Meng Yang; George Luiken; Eugene Baranov; Robert M Hoffman
Journal:  Biotechniques       Date:  2005-08       Impact factor: 1.993

2.  Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.

Authors:  B Sadeghi; C Arvieux; O Glehen; A C Beaujard; M Rivoire; J Baulieux; E Fontaumard; A Brachet; J L Caillot; J L Faure; J Porcheron; J L Peix; Y François; J Vignal; F N Gilly
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').

Authors:  Masaki Taki; Shunsuke Kagawa; Masahiko Nishizaki; Hiroyuki Mizuguchi; Takao Hayakawa; Satoru Kyo; Katsuyuki Nagai; Yasuo Urata; Noriaki Tanaka; Toshiyoshi Fujiwara
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

4.  Whole-body imaging with fluorescent proteins.

Authors:  Robert M Hoffman; Meng Yang
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

Review 6.  Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy.

Authors:  Paul H Sugarbaker
Journal:  Oncology (Williston Park)       Date:  2004-02       Impact factor: 2.990

7.  Telomerase-specific replication-selective virotherapy for human cancer.

Authors:  Takeshi Kawashima; Shunsuke Kagawa; Naoya Kobayashi; Yoshiko Shirakiya; Tatsuo Umeoka; Fuminori Teraishi; Masaki Taki; Satoru Kyo; Noriaki Tanaka; Toshiyoshi Fujiwara
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

8.  Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.

Authors:  Tatsuo Umeoka; Takeshi Kawashima; Shunsuke Kagawa; Fuminori Teraishi; Masaki Taki; Masahiko Nishizaki; Satoru Kyo; Katsuyuki Nagai; Yasuo Urata; Noriaki Tanaka; Toshiyoshi Fujiwara
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

Review 9.  Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options.

Authors:  Paul H Sugarbaker
Journal:  Oncology (Williston Park)       Date:  2004-01       Impact factor: 2.990

10.  ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment.

Authors:  Herbert Stepp; Tobias Beck; Thomas Pongratz; Thomas Meinel; Friedrich-Wilhelm Kreth; Jörg Ch Tonn; Walter Stummer
Journal:  J Environ Pathol Toxicol Oncol       Date:  2007       Impact factor: 3.567

View more
  69 in total

1.  Mass spectrometry imaging as a tool for surgical decision-making.

Authors:  David Calligaris; Isaiah Norton; Daniel R Feldman; Jennifer L Ide; Ian F Dunn; Livia S Eberlin; R Graham Cooks; Ferenc A Jolesz; Alexandra J Golby; Sandro Santagata; Nathalie Y Agar
Journal:  J Mass Spectrom       Date:  2013-11       Impact factor: 1.982

2.  Shedding New Light on the Use of Imaging Technology for Glioblastoma Tumor Resection.

Authors:  John Nemunaitis; Neil Senzer
Journal:  Mol Ther       Date:  2015-07       Impact factor: 11.454

3.  GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam® histoculture.

Authors:  Shuya Yano; Kiyoto Takehara; Shinji Miwa; Hiroyuki Kishimoto; Hiroshi Tazawa; Yasuo Urata; Shunsuke Kagawa; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-02-23       Impact factor: 2.416

4.  Enzymatically activated near infrared nanoprobes based on amphiphilic block copolymers for optical detection of cancer.

Authors:  Tuğba Özel; Sean White; Elaine Nguyen; Austin Moy; Nicholas Brenes; Bernard Choi; Tania Betancourt
Journal:  Lasers Surg Med       Date:  2015-07-17       Impact factor: 4.025

5.  Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer.

Authors:  Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet
Journal:  Hepatogastroenterology       Date:  2012-09

6.  Intraoperative near-infrared imaging of surgical wounds after tumor resections can detect residual disease.

Authors:  Brian Madajewski; Brendan F Judy; Anas Mouchli; Veena Kapoor; David Holt; May D Wang; Shuming Nie; Sunil Singhal
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

Review 7.  New strategies for fluorescent probe design in medical diagnostic imaging.

Authors:  Hisataka Kobayashi; Mikako Ogawa; Raphael Alford; Peter L Choyke; Yasuteru Urano
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

8.  Polychromatic in vivo imaging of multiple targets using visible and near infrared light.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Peter L Choyke
Journal:  Adv Drug Deliv Rev       Date:  2012-12-07       Impact factor: 15.470

9.  Fluorescence-guided surgery of human colon cancer increases complete resection resulting in cures in an orthotopic nude mouse model.

Authors:  Cristina A Metildi; Sharmeela Kaushal; Cynthia S Snyder; Robert M Hoffman; Michael Bouvet
Journal:  J Surg Res       Date:  2012-09-07       Impact factor: 2.192

10.  Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in orthotopic mouse models.

Authors:  Cristina A Metildi; Csilla N Felsen; Elamprakash N Savariar; Quyen T Nguyen; Sharmeela Kaushal; Robert M Hoffman; Roger Y Tsien; Michael Bouvet
Journal:  Ann Surg Oncol       Date:  2014-10-16       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.